Dihydroartemisinin targets the miR-497-5p/SOX5 axis to suppress tumor progression in non-small cell lung cancer
Frontiers in Pharmacology · 08.07.2025 · 16
DOI: 10.3389/fphar.2025.1605531 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 08.07.2025. Verfasst von Qing-Hua Yin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Yueyang Central Hospital, Yueyang, Hunan, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Non-small cell lung cancer (NSCLC) remains a lethal malignancy with limited therapeutic options. Although dihydroartemisinin (DHA) exhibits anticancer properties, its mechanisms in NSCLC are incompletely understood. This study investigated the role of the miR-497-5p/SOX5 axis in mediating DHA’s effects on NSCLC.
Methods
In vitro experiments utilized A549 and H1299 cells treated with DHA (50 μM). Proliferation, migration, invasion, and apoptosis were assessed. miR-497-5p and SOX5 expression was modulated via genetic silencing. In vivo , A549 xenograft tumor growth in mice was evaluated under DHA treatment (25/50 mg/kg).
Results
DHA significantly suppressed proliferation, migration, and invasion while inducing apoptosis in vitro . Mechanistically, DHA upregulated miR-497-5p and downregulated SOX5—overexpressed in clinical NSCLC. Silencing miR-497-5p attenuated DHA’s effects and increased SOX5, whereas SOX5 knockdown reversed miR-497-5p inhibition. In vivo , DHA dose-dependently inhibited tumor growth with miR-497-5p elevation and SOX5 suppression, effects abrogated by miR-497-5p inhibition but rescued by SOX5 knockdown.
Discussion
DHA exerts antitumor activity by activating the miR-497-5p/SOX5 axis, revealing a novel mechanism. Bridging efficacious in vitro concentrations with clinically achievable dosing remains essential for therapeutic translation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Yueyang Central Hospital, Yueyang, Hunan, China.
Zitieren
APA
Yin, Q. H., Zhou, Q., Hu, J. B., Weng, J., Shen, E. D., Wen, F., Liu, S. L., Yin, L. L., Tong, Y. J., Long, L., Tang, K. W., Bai, S. T., & Ou, L. D. (2025). Dihydroartemisinin targets the miR-497-5p/SOX5 axis to suppress tumor progression in non-small cell lung cancer. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1605531
Vancouver
Yin QH, Zhou Q, Hu JB, Weng J, Shen ED, Wen F, et al. Dihydroartemisinin targets the miR-497-5p/SOX5 axis to suppress tumor progression in non-small cell lung cancer. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1605531
BibTeX
@article{Yin2025,
author = {Yin, Qing-Hua and Zhou, Qiang and Hu, Jian-Bing and Weng, Jie and Shen, Er-Dong and Wen, Fang and Liu, Song-Lian and Yin, Lei-Lan and Tong, Ya-Jun and Long, Ling and Tang, Ke-Wei and Bai, Si-Te and Ou, Lu-Di},
title = {Dihydroartemisinin targets the miR-497-5p/SOX5 axis to suppress tumor progression in non-small cell lung cancer},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1605531}
}
EUVIMED